首页> 外文期刊>Oncology letters. >Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma
【24h】

Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma

机译:用于预测切除胰腺癌患者预后的新型列线图的开发和验证

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

abstract_textpThe survival prediction for patients with resected pancreatic adenocarcinoma by using the Tumor-Node-Metastasis (TNM) staging system remains limited. A nomogram is a efficient tool that can be used to predict the outcome of patients with various types of malignancy. The present study aimed to develop and validate a nomogram for patients with resected pancreatic adenocarcinoma. A total of 368 patients (258 in the training set and 110 in the validation set) who underwent pancreatic adenocarcinoma resection at the China National Cancer Center between January 2008 and October 2018 were included in the present study. The nomogram was established according to the results from Cox multivariate analysis, which was validated by discrimination and calibration. The area under the receiver operating characteristic curve (AUC) was determined to assess the accuracy of survival predictions. The results from multivariate analysis in the training set demonstrated that blood transfusion, T-stage, N-stage, tumor grade, capsule invasion, carbohydrate antigen 199, neutrophil percentage and adjuvant therapy were independent prognostic factors for overall survival (OS; all P0.05). Subsequently, a nomogram predicting the 1-year, 3-year and 5-year OS rates, with favorable calibration, was established based on the independent prognostic factors. The concordance indices of the nomogram were higher compared with the TNM staging system in both training and validation sets. Furthermore, a clear risk stratification system based on the nomogram was used to classify patients into the three following groups: Low-risk group (less than or equal to168), moderate-risk group (168-255) and high-risk group (255). The risk stratification system demonstrated an improved ability in predicting the 1-year, 3-year and 5-year OS rates compared with the TNM system (AUC, 0.758, 0.709 and 0.672 vs. AUC, 0.614, 0.604 and 0.568; all P0.05). The present study developed and validated a nomogram for patients with resected pancreatic adenocarcinoma by including additional independent prognostic factors, including tumor marker, immune index, surgical information, pathological data and adjuvant therapy. Taken together, the results from the present study indicated an improved performance of the nomogram in predicting the prognosis of patients with resected pancreatic adenocarcinoma compared with the TNM staging system./p/abstract_text
机译:使用肿瘤-淋巴结-转移 (TNM) 分期系统对切除胰腺癌患者的生存预测仍然有限。列线图是一种有效的工具,可用于预测各种类型恶性肿瘤患者的预后。本研究旨在开发和验证切除胰腺癌患者的列线图。本研究共纳入 2008 年 1 月至 2018 年 10 月在中国国家癌症中心接受胰腺癌切除术的 368 例患者(训练组 258 例,验证组 110 例)。根据Cox多变量分析结果建立列线图,并通过判别和校准进行验证。确定受试者工作特征曲线下面积 (AUC) 以评估生存预测的准确性。训练集多因素分析结果显示,输血、T分期、N分期、肿瘤分级、荚膜浸润、碳水化合物抗原199、中性粒细胞百分比和辅助治疗是总生存期(OS)的独立预后因素,P均168)、中风险组(168-255)和高风险组(>255)。与TNM系统相比,风险分层系统在预测1年、3年和5年OS率方面表现出更好的能力(AUC,0.758、0.709和0.672 vs. AUC,0.614、0.604和0.568;均P

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号